TY - JOUR
T1 - Cancer of the ovary
AU - Lurain, John
AU - Mckay, Michael J.
AU - Bull, Colin A.
AU - Collazos, Julio
AU - Embil, John M.
AU - Cannistra, Stephen A.
PY - 1994/4/7
Y1 - 1994/4/7
N2 - To the Editor: Dr. Cannistra stated in his review article on cancer of the ovary (Nov. 18 issue)1 that “the regimen of cisplatin plus cyclophosphamide is just as effective as more complicated and toxic regimens, such as those containing altretamine or doxorubicin hydrochloride.” It appears that the author did not review the literature critically. For example, Hainsworth et al. (Cannistra's reference 42) reported a response rate of 96 percent for the combination of altretamine (hexamethylmelamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP)2. More important, the median survival for the entire group of patients was 45 months, and it was 72 months.
AB - To the Editor: Dr. Cannistra stated in his review article on cancer of the ovary (Nov. 18 issue)1 that “the regimen of cisplatin plus cyclophosphamide is just as effective as more complicated and toxic regimens, such as those containing altretamine or doxorubicin hydrochloride.” It appears that the author did not review the literature critically. For example, Hainsworth et al. (Cannistra's reference 42) reported a response rate of 96 percent for the combination of altretamine (hexamethylmelamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP)2. More important, the median survival for the entire group of patients was 45 months, and it was 72 months.
UR - http://www.scopus.com/inward/record.url?scp=0028767309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028767309&partnerID=8YFLogxK
U2 - 10.1056/NEJM199404073301415
DO - 10.1056/NEJM199404073301415
M3 - Letter
C2 - 8155171
AN - SCOPUS:0028767309
SN - 0028-4793
VL - 330
SP - 1012
EP - 1014
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 14
ER -
